MediciNova completes last patient visit in COMBAT-ALS Phase 2b/3 trial of MN-166 ibudilast
MNOV•MediciNova completed the last patient visit in the double-blind portion of its COMBAT-ALS Phase 2b/3 trial of MN-166. Topline results are expected by the end of 2026, and the full study’s final visit is expected in March 2027.
1. Trial milestone
The study is assessing whether MN-166 can slow overall disease worsening while maintaining an acceptable safety and tolerability profile. The update keeps the program on track for data lock and analysis.
